Abbotts Labs: tihtens up annual targets
(CercleFinance.com) - Abbott Laboratories has tightened up its target ranges for adjusted EPS and organic sales growth (excluding Covid-19 test revenues), to $4.
61-$4.71 and 9.5%-10% respectively, for the current year.
For Q2 2024, it reports adjusted EPS of $1.14, on revenues that are up 4% to $10.4bn, underlining the continued strength of the underlying core business.
In organic terms and excluding sales linked to Covid-19 tests, the healthcare group's sales rose by 9.3%, notably driven by double-digit growth in medical devices (+12.1%).
Copyright (c) 2024 CercleFinance.com. All rights reserved.
61-$4.71 and 9.5%-10% respectively, for the current year.
For Q2 2024, it reports adjusted EPS of $1.14, on revenues that are up 4% to $10.4bn, underlining the continued strength of the underlying core business.
In organic terms and excluding sales linked to Covid-19 tests, the healthcare group's sales rose by 9.3%, notably driven by double-digit growth in medical devices (+12.1%).
Copyright (c) 2024 CercleFinance.com. All rights reserved.